Drug Profile


Alternative Names: Albenza; Bilutac®; Escazole®; Eskazole®; Proftril®; SKF 62979; Zentel®

Latest Information Update: 07 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; PharmAust
  • Class Anthelmintics; Benzimidazoles; Carbamates; Small molecules
  • Mechanism of Action Tubulin inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Helminthiasis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Helminthiasis
  • Phase I/II Ascites

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Helminthiasis(In volunteers) in China (PO, Tablet)
  • 31 May 2013 Phase-I/II clinical trials in Ascites in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top